1/ Key data presented #ASH20 from the FORTE, EMN02 and IFM-2009 trials further strengthen the role of transplant in myeloma. FORTE trial also provides key randomized data for dual maintenance. #mmsm #bmtsm Highlights below.
2/ Higher sustained MRD negativity and PFS benefit with KRD-ASCT vs KRD in the FORTE trial presented by Dr. Francesca Gay.
KR maintenance also leads to improved outcomes in all subgroups vs R maintenance alone. #mmsm #ASH20
KR maintenance also leads to improved outcomes in all subgroups vs R maintenance alone. #mmsm #ASH20
3/ IFM 2009 trial: Known higher MRD negativity and better PFS with early vs delayed ASCT.
Even amongst MRD negative group, those in the early SCT group have better PFS.
Similar OS and PFS-2 with early vs. delayed SCT.
3/4th pts in delayed grp received transplant at relapse
Even amongst MRD negative group, those in the early SCT group have better PFS.
Similar OS and PFS-2 with early vs. delayed SCT.
3/4th pts in delayed grp received transplant at relapse
4/ EMN-02 trial update: Better OS and PFS-2 in patients undergoing upfront ASCT.
OS data required long term follow-up of over 75 months.
About half of the pts in non-transplant group received SCT at relapse. #ASH20 #mmsm #bmtsm
OS data required long term follow-up of over 75 months.
About half of the pts in non-transplant group received SCT at relapse. #ASH20 #mmsm #bmtsm
• • •
Missing some Tweet in this thread? You can try to
force a refresh
